Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.51 |
| ▸ | TOP1 | P11387 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395094 | 0.88 | CHRM1 (0.49) | CHRM1TOP1LMNAFABP4FABP3 | |
| SCHEMBL2396901 | 0.87 | TOP1 (0.40) | CHRM1TOP1LMNAFABP4 | |
| SCHEMBL2392743 | 0.86 | CHRM1 (0.49) | CHRM1TOP1LMNAFABP4FABP3 | |
| SCHEMBL2396353 | 0.80 | CHRM1 (0.59) | CHRM1TOP1LMNAFABP4FABP3 | |
| SCHEMBL8010027 | 0.77 | CHRM1 (0.56) | CHRM1TOP1LMNA | |
| SCHEMBL15579846 | 0.76 | CHRM1 (0.52) | CHRM1TOP1LMNA | |
| SCHEMBL2397468 | 0.74 | CHRM1 (0.53) | CHRM1TOP1LMNA | |
| SCHEMBL2393836 | 0.73 | CHRM1 (0.49) | CHRM1TOP1LMNA | |
| SCHEMBL8010332 | 0.73 | CHRM1 (0.49) | CHRM1TOP1LMNA | |
| SCHEMBL15520369 | 0.73 | CHRM1 (0.38) | CHRM1TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252299-B1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8022215-B2 | Fused pyridone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022215-B2 | Fused pyridone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2009102588-A1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885TOP1 4432/4885LMNA 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.